Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.
about
Translating the epitranscriptomeHuman iPSC for Therapeutic Approaches to the Nervous System: Present and Future ApplicationsRNA-Based Vaccines in Cancer ImmunotherapyThe Epitranscriptome and Innate ImmunityRecombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondEngine out of the chassis: cell-free protein synthesis and its usesN6-methyl-adenosine modification in messenger and long non-coding RNAThe oral and craniofacial relevance of chemically modified RNA therapeuticsHighly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.Zika virus protection by a single low-dose nucleoside-modified mRNA vaccinationNebulisation of IVT mRNA Complexes for Intrapulmonary Administration.mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation.Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarctionOrgan-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery.Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis.Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNAmRNA vaccine delivery using lipid nanoparticles.The notorious R.N.A. in the spotlight - drug or target for the treatment of diseaseChemical and structural effects of base modifications in messenger RNA.Towards mRNA with superior translational activity: synthesis and properties of ARCA tetraphosphates with single phosphorothioate modifications.Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation.Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies.The dynamic epitranscriptome: N6-methyladenosine and gene expression controlIn vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle.Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAARTTranscriptome-wide mapping of pseudouridines: pseudouridine synthases modify specific mRNAs in S. cerevisiae.Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase LGenerating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA.mRNA leapfrogs DNA to show promise for therapeutic gene transferA Recombinant Collagen-mRNA Platform for Controllable Protein SynthesisSelf-assembled Messenger RNA Nanoparticles (mRNA-NPs) for Efficient Gene Expression.Nucleofection induces transient eIF2α phosphorylation by GCN2 and PERK.Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.mRNA-Mediated Gene Supplementation of Toll-Like Receptors as Treatment Strategy for Asthma In Vivo.Pseudouridine: still mysterious, but never a fake (uridine)!Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases.Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format.Developing mRNA-vaccine technologies.
P2860
Q26747114-37BCD127-7AF8-4FCF-B8B6-16B9634F0B6BQ26772309-21DF5DE8-0EE3-46F3-86D3-1D47394C78AAQ26776028-B32516B4-5038-42AF-8623-83EFB7F5D2E9Q26776423-94F4954F-B8F6-4EEF-917A-A20C9A2FFC6BQ26861563-CCC4ADC6-E1D7-40FB-9235-361D831A5DD8Q26994662-56F41D46-5474-44AD-8CAB-8274DD23FFEBQ27022522-2CAAC8F5-FB26-48D2-8560-6DD3D31863D4Q28072338-1785AAA7-08C7-4639-9E80-FA22BB3E3EFBQ28131663-330FC480-6D29-422C-A5DA-42DA41D958D4Q28656365-D3DF4488-67D1-415B-BBEC-6E5D2637A401Q30402786-74562F2E-AFB1-4E17-8954-B73C0D33265CQ30548207-6A0C48BE-F5E5-4B2A-BCCA-AD041A684540Q30580723-B95C1C29-9AAA-4767-94EC-68251D6B2A2AQ30624869-9D69D27E-2EC4-4FB4-A8AB-727810C2FC29Q30690412-0EAF71BA-49E7-4E25-B5B0-F9200D20D021Q33652543-4B9F569A-D1AB-48B3-94B2-6E527D9C8AABQ33711685-1B55BA16-980B-4342-AA8E-08843248A5E3Q33739733-38FE4EB9-8706-4389-BDF4-FCB54586F38BQ33876249-43063527-AF3F-4533-BAE8-0730ECD4DE9AQ34055104-5203437C-B3FA-44B3-B1E2-36A91B6DF3DBQ34146278-B3DEE9DF-7B19-4F95-8BC7-584397AC6F04Q34234240-94F0BAEF-4C1A-4B88-8597-6014D0D73CA6Q34414288-02A1482D-BABF-4D71-AA52-4B2BED251143Q34589906-91E0E653-DE84-4743-B26A-A96A402FD9F2Q34647798-33CA6C38-99A0-4A5F-9164-E826DEC4CBDBQ35374452-881BAFED-ABC4-49D2-A276-C3A9A49A4753Q35620847-F28ED573-7CC7-45CB-83FB-C08181F2BE2BQ35620919-D3372F97-5E6C-4BB5-94D2-28B958F1904EQ35677482-D97388A2-AA98-47B3-B23D-DFA4B7ED1B04Q35876177-5BF205EF-D247-4EB0-90EF-B6CE9CE21305Q35895269-1506AF6A-D65A-40A7-AD7F-EE690C72A9C4Q35909697-F000DFD7-10E9-41E8-A7F7-027E6EECBC5BQ35936953-A4F749B9-23A0-4169-9291-5C9DA4F3FCFAQ35939486-F1415F8D-911C-4A87-B05E-58BA8A62687FQ35996243-86884121-A13F-46B6-ADB7-0806B5D09501Q36190987-2B5FACEE-A202-4D2A-8274-A3BA237CD852Q36216226-28D781FD-CC51-4248-BD9A-A67B17986F72Q36218294-D34E6F30-9DD9-4923-8434-7A80D25FADC3Q36673897-88A1FE04-0EE3-45AE-8A6F-98D5A730BB60Q36684597-6F7B6DC0-BCA1-44D9-AF26-94D732516741
P2860
Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incorporation of pseudouridine ...... city and biological stability.
@en
Incorporation of pseudouridine ...... city and biological stability.
@nl
type
label
Incorporation of pseudouridine ...... city and biological stability.
@en
Incorporation of pseudouridine ...... city and biological stability.
@nl
prefLabel
Incorporation of pseudouridine ...... city and biological stability.
@en
Incorporation of pseudouridine ...... city and biological stability.
@nl
P2093
P2860
P356
P1433
P1476
Incorporation of pseudouridine ...... city and biological stability.
@en
P2093
Drew Weissman
Frank A Welsh
Hiroki Kato
Hiromi Muramatsu
János Ludwig
Katalin Karikó
Shizuo Akira
P2860
P304
P356
10.1038/MT.2008.200
P577
2008-09-16T00:00:00Z